Approximately 40 million individuals worldwide have been infected with SARS-CoV-2, the virus responsible for the novel coronavirus disease-2019 (COVID-19). Despite the current literature about the cardiac effects of COVID-19 in children, more information is required. We aimed to determine both cardiovascular and arrhythmia assessments via electrocardiographic and echocardiographic parameters. We evaluated 70 children who were hospitalized with COVID-19 infections and 70 children as the normal control group through laboratory findings, electrocardiography (ECG), and transthoracic echocardiography (TTE). We observed significantly increased levels of Tp-Te, Tp-Te/QT, and Tp-Te/QTc compared with the control group. Twenty-five of 70 (35.7%) patients had fragmented QRS(fQRS) without increased troponin levels. None of the patients had pathologic corrected QT(QTc) prolongation during the illness or its treatment. On TTE, 20 patients had mild mitral insufficiency, among whom only five had systolic dysfunction (ejection fraction <55%). There was no significant difference between the patient and control groups, except for isovolumic relaxation time (IVRT) in terms of mean systolic and diastolic function parameters. The IVRT of COVID patients was significantly lower than that of control group. Despite all the adult studies, the effects of COVID?19 on myocardial function are not well established in children. The thought that children are less affected by the illness may be a misconception.
13 July 2024 in Journal of Antimicrobial Chemotherapy
Background: Fosfomycin is gaining increasing attention for its activity against MDR or XDR pathogens. Currently, IV fosfomycin is a potential option for treating various infections, including urinary tract infections, pneumonia and skin infections when first-line treatments fail. Objectives: To evaluate the demographic, clinical, microbiological and treatment modality of children received IV fosfomycin to treat infections caused by MDR pathogens since there are few data on the use of fosfomycin in children. Methods: This study was conducted retrospectively with patients under 18 years of age who were treated with IV fosfomycin for at least 72 h due to infections caused by MDR pathogens between January 2019 and October 2023 at Marmara University Pendik Training and Research Hospital, İstanbul, Türkiye. Data on demographic and clinical features, microbiological findings, treatment modalities and side effects were evaluated. Results: Twenty-five children, for a total of 32 cases of infection episodes, with a mean age of 11.4 ± 3.92 years who received IV fosfomycin were included. The most frequent comorbidity was chronic pulmonary diseases, and the most common infection needed for IV fosfomycin was MDR Pseudomonas aeruginosa pneumonia. In all cases, fosfomycin was administered in combination with other antibiotics, mainly meropenem–colistin (68.7%) or meropenem (15.6%). Twenty-two (71.9%) cases had favourable clinical responses at the end of therapy. Conclusions: Our results suggest that IV fosfomycin may be an effective treatment option for MDR pathogens in the paediatric population. Nevertheless, careful stewardship is necessary to maintain efficacy and reduce antimicrobial resistance selection risk.
22 March 2024 in Flora the Journal of Infectious Diseases and Clinical Microbiology
Introduction: Listeria monocytogenes is a Gram-positive bacillus that causes severe infections mainly in newborns, pregnant women, immunocompromised individuals, and elderly. In this report, we present a case of immune dysregulation that presented with invasive Listeria infection despite the absence of these risk factors. Case: A previously healthy 5-year-old girl developed L. monocytogenes meningitis, which is unusual given her age and lack of typical risk factors. The patient initially presented with fever, diarrhea and altered mental status, unresponsive to empiric antibiotic treatment. Besides clinical diagnosis of meningitis, laboratory tests revealed pleocytosis and positive polymerase chain reaction test for L. monocytogenes in cerebrospinal fluid. Despite initial improvement, the patient developed proteinuria and hypertension and was later diagnosed with focal class 3 lupus nephritis following a renal biopsy. Given the atypical nature of her L. monocytogenes infection, persistent organomegaly, and lupus nephritis, further immunological evaluation was conducted. Genetic testing revealed a de-novo gain-of-function mutation in the PIK3CD gene, confirming the diagnosis of Activated Phosphoinositide 3-Kinase Delta Syndrome 1 (APDS1), a rare primary immunodeficiency characterized by lymphoproliferation and autoimmunity. The patient was started on immunoglobulin replacement therapy and prophylactic trimethoprim-sulfamethoxazole. No recurrence of severe infection occurred during 2 years of follow-up. Conclusion: This case underscores the importance of considering underlying immune dysregulations in pediatric patients with atypical presentation of Listeria infections.